Correlation between docetaxel-induced skin toxicity and the use of steroids and H2 blockers: a multi-institution survey

  • K. Kawaguchi
  • H. Ishiguro
  • S. Morita
  • S. Nakamura
  • S. Ohno
  • N. Masuda
  • H. Iwata
  • K. Aogi
  • K. Kuroi
  • M. Toi
  • Japan Breast Cancer Research Group (JBCRG)
Epidemiology

DOI: 10.1007/s10549-011-1641-9

Cite this article as:
Kawaguchi, K., Ishiguro, H., Morita, S. et al. Breast Cancer Res Treat (2011) 130: 627. doi:10.1007/s10549-011-1641-9

Abstract

Steroids and H2 blockers are commonly used as supportive care for taxane-containing chemotherapy, but they also affect docetaxel’s primary metabolizer, cytochrome P450 3A4. This retrospective observational study was performed to better understand the effects of these compounds on docetaxel-induced skin toxicities, specifically hand-foot syndrome (HFS) and facial erythema (FE), a relationship that is currently poorly understood. Member institutions of the Japan Breast Cancer Research Group were invited to complete a questionnaire on the occurrence of grade 2 or higher HFS and FE among patients treated between April 2007 and March 2008 with docetaxel as an adjuvant or neoadjuvant chemotherapeutic treatment for breast cancer. We obtained data for 993 patients from 20 institutions. Twenty percent received H2 blockers, and all patients received dexamethasone. Univariate and multivariate analyses revealed that H2 blockers are associated with a significantly higher incidence of both HFS and FE. The incidence of FE was significantly higher for the docetaxel + cyclophosphamide (TC) regimen than for non-TC regimens combined. Dexamethasone usage did not affect the incidence of either HFS or FE. In conclusion, use of H2 blockers as premedication in breast cancer patients receiving docetaxel significantly increases the risk of both HFS and FE.

Keywords

CYP3A4 Docetaxel Drug exposure Facial erythema Hand-foot syndrome H2 blocker 

Copyright information

© Springer Science+Business Media, LLC. 2011

Authors and Affiliations

  • K. Kawaguchi
    • 1
    • 2
  • H. Ishiguro
    • 3
  • S. Morita
    • 4
  • S. Nakamura
    • 5
  • S. Ohno
    • 6
  • N. Masuda
    • 7
  • H. Iwata
    • 8
  • K. Aogi
    • 9
  • K. Kuroi
    • 10
  • M. Toi
    • 1
  • Japan Breast Cancer Research Group (JBCRG)
  1. 1.Department of Breast SurgeryKyoto University HospitalKyotoJapan
  2. 2.Department of SurgeryOsaka Red Cross HospitalOsakaJapan
  3. 3.Outpatient Oncology UnitKyoto University HospitalKyotoJapan
  4. 4.Department of Biostatistics and EpidemiologyYokohama City University Medical CenterYokohamaJapan
  5. 5.Breast CenterShowa University HospitalTokyoJapan
  6. 6.Division of Breast OncologyNational Kyushu Cancer CenterFukuokaJapan
  7. 7.Department of Surgery, Breast OncologyOsaka National HospitalOsakaJapan
  8. 8.Department of Breast OncologyAichi Cancer Center HospitalNagoyaJapan
  9. 9.Department of Breast OncologyNational Hospital Organization Shikoku Cancer CenterMatsuyamaJapan
  10. 10.Department of Surgery, Division of Clinical Trials and ResearchTokyo Metropolitan Cancer and Infectious Diseases Center Komagome HospitalTokyoJapan